| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0021-9150(87)90110-9 |
| P8608 | Fatcat ID | release_onreqmapvffv7inocoezepgez4 |
| P698 | PubMed publication ID | 3827975 |
| P50 | author | Johannes Nimpf | Q73020043 |
| P2093 | author name string | J Nimpf | |
| G M Kostner | |||
| H Wurm | |||
| P433 | issue | 2-3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 109-14 | |
| P577 | publication date | 1987-02-01 | |
| P1433 | published in | Atherosclerosis | Q4813570 |
| P1476 | title | Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation | |
| P478 | volume | 63 |
| Q28195850 | 21-year-old patient with myocardial infarct, transient cerebral ischemia and thrombocytopenia |
| Q33330540 | A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies |
| Q33350227 | A new player in the antiphospholipid syndrome: the beta 2 glycoprotein I cofactor |
| Q28207774 | A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection |
| Q39522738 | A possible coagulation-independent mechanism for pregnancy loss involving β(2) glycoprotein 1-dependent antiphospholipid antibodies and CD1d |
| Q33915467 | Accelerated atheroma and anti-beta2-glycoprotein I antibodies |
| Q30846733 | Analysis of T cell responses to the beta 2-glycoprotein I-derived peptide library in patients with anti-beta 2-glycoprotein I antibody-associated autoimmunity |
| Q34790028 | Anti-beta 2-glycoprotein I autoantibodies and atherosclerosis |
| Q24558202 | Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) |
| Q61837014 | Antibodies to beta2 glycoprotein I are associated with in vitro fertilization implantation failure as well as recurrent miscarriage: results of a prevalence study |
| Q40399658 | Antigenic specificities of "antiphospholipid" autoantibodies |
| Q33433833 | Antiphospholipid Antibodies and Associated Clinical Manifestations |
| Q57825441 | Antiphospholipid Antibodies in Patients with Lupus Nephritis |
| Q73086663 | Antiphospholipid antibodies and the antiphospholipid antibody syndrome |
| Q45763284 | Antiphospholipid antibodies differ in aPL cofactor requirement |
| Q41682862 | Antiphospholipid antibodies or not? The role of beta 2 glycoprotein 1 in autoantibody-mediated pregnancy loss |
| Q28193967 | Antiphospholipid antibodies: biological basis and prospects for treatment |
| Q33382848 | Antiphospholipid antibodies: paradigm in transition |
| Q33491626 | Antiphospholipid antibodies: specificity and pathophysiology |
| Q35099505 | Antiphospholipid syndrome: an overview. |
| Q35216326 | Antiphospholipid syndrome: genetic review |
| Q50954545 | Apolipoprotein H levels in diabetic subjects: correlation with cholesterol levels. |
| Q77746573 | Apoptosis and antiphospholipid antibodies |
| Q36951070 | Atherogenic antiphospholipid antibodies in antiphospholipid syndrome |
| Q33232688 | Autoantibodies in Argentine women with recurrent pregnancy loss |
| Q41645294 | Autoantibody response and pregnancy-related pathology induced by combined LPS and tetanus toxoid hyperimmunization in BALB/c and C57BL/6 mice. |
| Q37095385 | Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I. |
| Q40558449 | Beta 2-glycoprotein I. |
| Q40036677 | Beta-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members |
| Q74211615 | Beta2-glycoprotein I-dependent and -independent anticardiolipin antibody in non-obese diabetic (NOD) mice |
| Q35631774 | Bouquet variety of antiphospholipid antibodies in recurrent pregnancy loss |
| Q61415570 | Chapter 5 Tissue Factor in Antiphospholipid Antibody-induced Pregnancy Loss: Thrombosis versus Inflammation |
| Q38338843 | Characterization and representative structures of N-oligosaccharides bound to apolipoprotein H. |
| Q41921283 | Characterization of binding of human beta 2-glycoprotein I to cardiolipin |
| Q41989452 | Circulating anti-beta2-glycoprotein I antibodies are associated with endothelial dysfunction, inflammation, and high nitrite plasma levels in patients with intermittent claudication |
| Q40585799 | Cloning and characterization of the human beta2-glycoprotein I (beta2-GPI) gene promoter: roles of the atypical TATA box and hepatic nuclear factor-1alpha in regulating beta2-GPI promoter activity |
| Q41674799 | Complete nucleotide and deduced amino acid sequence of human β2-glycoprotein I |
| Q43719415 | Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies |
| Q41545004 | Expression of anticardiolipin cofactor, human beta 2-glycoprotein I, by a recombinant baculovirus/insect cell system |
| Q38317583 | Expression of human recombinant beta 2-glycoprotein I with anticardiolipin antibody cofactor activity |
| Q43801367 | Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome |
| Q35025284 | Herbal factors in the treatment of autoimmunity-related habitual abortion |
| Q72131296 | Heterogeneity of the apolipoprotein H*3 allele and its role in affecting the binding of apolipoprotein H (beta 2-glycoprotein I) to anionic phospholipids |
| Q33379907 | Immunology and Clinical Importance of Antiphospholipid Antibodies |
| Q28593655 | Impaired thrombin generation in beta 2-glycoprotein I null mice |
| Q41197483 | In vivo models of thrombosis for the antiphospholipid syndrome |
| Q35604834 | Interaction of β2-glycoprotein I with lipopolysaccharide leads to Toll-like receptor 4 (TLR4)-dependent activation of macrophages |
| Q33498334 | Isolation and purification of anticardiolipin antibody from plasma of a patient with antiphospholipid syndrome: induced generation of platelet thromboxane A2 synthesis |
| Q34052004 | Lessons from BXSB and related mouse models |
| Q45871813 | Low serum lipoprotein(a) and beta 2-glycoprotein I levels in HIV-1-positive hemophiliacs |
| Q35822631 | Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I |
| Q44043907 | Lupus-like anticoagulant properties of murine monoclonal antibodies to beta 2-glycoprotein I |
| Q40400869 | Molecular studies on phospholipid-binding sites and cryptic epitopes appearing on beta 2-glycoprotein I structure recognized by anticardiolipin antibodies |
| Q77796443 | Opposite beta2-glycoprotein I requirement for the binding of infectious and autoimmune antiphospholipid antibodies to cardiolipin liposomes is associated with antibody avidity |
| Q35399567 | Optimising testing for phospholipid antibodies |
| Q33503275 | Origin and pathogenesis of antiphospholipid antibodies |
| Q33498327 | Pathogenesis and treatment of the antiphospholipid antibody syndrome |
| Q69611546 | Phenotypic effects of apolipoprotein structural variation on lipid profiles. I. APO H and quantitative lipid measures in the healthy women study |
| Q69417097 | Phenotypic effects of apolipoprotein structural variation on lipid profiles. IV. Apolipoprotein polymorphisms in a small group of black women from the healthy women study |
| Q72891413 | Plasma concentrations of total/free and functional protein S are not decreased in systemic lupus erythematosus patients with lupus anticoagulant and/or antiphospholipid antibodies |
| Q24293734 | Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis |
| Q39506588 | Platelet activation in normo- and hyperlipoproteinemias |
| Q33706238 | Platelet microparticles: a wide-angle perspective |
| Q47739764 | Prevalence of beta2-glycoprotein I antibody in patients with liver cirrhosis: relationship with beta2-glycoprotein I plasma levels and thrombosis |
| Q43283992 | Prospective study on autoantibodies against apolipoprotein H (beta2GPI) in several clinical parameters from patients with terminal renal failure and functioning renal transplants |
| Q36287542 | Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies |
| Q77849830 | Suppressive effect of anticardiolipin antibody on the proliferation of human umbilical vein endothelial cells |
| Q28143036 | T cells that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals |
| Q40977408 | The antiphospholipid-protein syndrome |
| Q35966558 | The role of antiphospholipid antibodies in stroke. |
| Q93020058 | The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS |
| Q47719662 | Thrombogenic properties of antiphospholipid antibodies do not depend on their binding to beta2 glycoprotein 1 (beta2GP1) alone |
| Q33497587 | beta 2-Glycoprotein I: target antigen for autoantibodies in the 'antiphospholipid syndrome'. |
| Q52081764 | beta2-Glycoprotein 1 as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss. |
Search more.